Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
Linjun Hu,1,* Qinxin Zhao,2,* Hongsong Bai,1 Chengming Xie,1 Xingli Shan,1 Dehu Lu,1 Yonghai Chen,1 Dongdong Han,1 Zejun Xiao,2 Jun Tian,2 Dong Wang,2 Xingang Bi,2 Nianzeng Xing2 1Department of Urology, Cancer Hospital of HuanXing Chaoyang District Beijing, Beijing, People’s Republic of Ch...
Main Authors: | Hu L, Zhao Q, Bai H, Xie C, Shan X, Lu D, Chen Y, Han D, Xiao Z, Tian J, Wang D, Bi X, Xing N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-06-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-androgen-deprivation-therapy-combined-with-doce-peer-reviewed-article-CMAR |
Similar Items
-
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
by: Whi-An Kwon, et al.
Published: (2019-05-01) -
The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01) -
Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection
by: R. A. Gafanov, et al.
Published: (2019-01-01) -
Choice of treatment options for metastatic hormone-sensitive prostate cancer
by: R. A. Gafanov, et al.
Published: (2020-12-01) -
Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)